These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 34459248)
1. Decision Threshold for Kryptor sFlt-1/PlGF Ratio in Women With Suspected Preeclampsia: Retrospective Study in a Routine Clinical Setting. Andersen LLT; Helt A; Sperling L; Overgaard M J Am Heart Assoc; 2021 Sep; 10(17):e021376. PubMed ID: 34459248 [TBL] [Abstract][Full Text] [Related]
2. Elecsys® and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable? Stepan H; Hund M; Dilba P; Sillman J; Schlembach D Clin Chem Lab Med; 2019 Aug; 57(9):1339-1348. PubMed ID: 31323000 [TBL] [Abstract][Full Text] [Related]
3. Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia. van Helden J; Weiskirchen R Clin Biochem; 2015 Nov; 48(16-17):1113-9. PubMed ID: 26129879 [TBL] [Abstract][Full Text] [Related]
4. The feasibility of soluble Fms-Like Tyrosine kinase-1 (sFLT-1) and Placental Growth Factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia. Aminuddin NA; Sutan R; Mahdy ZA; Rahman RA; Nasuruddin DN PLoS One; 2022; 17(3):e0265080. PubMed ID: 35275947 [TBL] [Abstract][Full Text] [Related]
5. Correlation of Kryptor and Elecsys® immunoassay sFlt-1/PlGF ratio on early diagnosis of preeclampsia and fetal growth restriction: A case-control study. Simón E; Herraiz I; Villalaín C; Gómez-Arriaga PI; Quezada MS; López-Jiménez EA; Galindo A Pregnancy Hypertens; 2020 Apr; 20():44-49. PubMed ID: 32172169 [TBL] [Abstract][Full Text] [Related]
6. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting. Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562 [TBL] [Abstract][Full Text] [Related]
7. A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome. Stepan H; Hund M; Gencay M; Denk B; Dinkel C; Kaminski WE; Wieloch P; Semus B; Meloth T; Dröge LA; Verlohren S Hypertens Pregnancy; 2016 Aug; 35(3):295-305. PubMed ID: 27028698 [TBL] [Abstract][Full Text] [Related]
8. sFlt-1/PlGF ratio predicts serious outcomes in confirmed early-onset preeclampsia. Shinohara S; Hiraoka N; Mochizuki K; Yasuda G; Kasai M; Sunami R Eur J Obstet Gynecol Reprod Biol; 2024 Sep; 300():159-163. PubMed ID: 39003888 [TBL] [Abstract][Full Text] [Related]
9. Prediction of preeclampsia with angiogenic biomarkers. Results from the prospective Odense Child Cohort. Andersen LB; Dechend R; Jørgensen JS; Luef BM; Nielsen J; Barington T; Christesen HT Hypertens Pregnancy; 2016 Aug; 35(3):405-19. PubMed ID: 27159383 [TBL] [Abstract][Full Text] [Related]
13. Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to Placental Growth Factor Ratio: A Prospective Cohort Study of Unselected Nulliparous Women. Sovio U; Gaccioli F; Cook E; Hund M; Charnock-Jones DS; Smith GC Hypertension; 2017 Apr; 69(4):731-738. PubMed ID: 28167687 [TBL] [Abstract][Full Text] [Related]
14. Economic assessment of the use of the sFlt-1/PlGF ratio test to predict preeclampsia in Germany. Schlembach D; Hund M; Schroer A; Wolf C BMC Health Serv Res; 2018 Aug; 18(1):603. PubMed ID: 30081904 [TBL] [Abstract][Full Text] [Related]
15. Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor)-Ratio in the Clinical Routine: A Real-World Study. Dröge LA; Perschel FH; Stütz N; Gafron A; Frank L; Busjahn A; Henrich W; Verlohren S Hypertension; 2021 Feb; 77(2):461-471. PubMed ID: 33280406 [TBL] [Abstract][Full Text] [Related]
16. Predictive value of soluble fms-like tyrosine kinase-1 against placental growth factor for preeclampsia in a Chinese pregnant women population. Yu F; Bai Q; Zhang S; Jiang Y J Clin Lab Anal; 2019 Jun; 33(5):e22861. PubMed ID: 30758082 [TBL] [Abstract][Full Text] [Related]
17. Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia. Graupner O; Karge A; Flechsenhar S; Seiler A; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B Arch Gynecol Obstet; 2020 Feb; 301(2):375-385. PubMed ID: 31734756 [TBL] [Abstract][Full Text] [Related]
18. Short-term prediction of preeclampsia using the sFlt-1/PlGF ratio: a subanalysis of pregnant Japanese women from the PROGNOSIS Asia study. Ohkuchi A; Saito S; Yamamoto T; Minakami H; Masuyama H; Kumasawa K; Yoshimatsu J; Nagamatsu T; Dietl A; Grill S; Hund M Hypertens Res; 2021 Jul; 44(7):813-821. PubMed ID: 33727707 [TBL] [Abstract][Full Text] [Related]
19. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. Zeisler H; Llurba E; Chantraine F; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Dilba P; Schoedl M; Hund M; Verlohren S N Engl J Med; 2016 Jan; 374(1):13-22. PubMed ID: 26735990 [TBL] [Abstract][Full Text] [Related]
20. Use of the sFlt-1/PlGF ratio to rule out preeclampsia requiring delivery in women with suspected disease. Is the evidence reproducible? Sabrià E; Lequerica-Fernández P; Ganuza PL; Ángeles EE; Escudero AI; Martínez-Morillo E; Alvárez FV Clin Chem Lab Med; 2018 Jan; 56(2):303-311. PubMed ID: 28841572 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]